Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease

References

1. ↵
   1. National Kidney Foundation

   (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–S266.

   OpenUrlCrossRefPubMedWeb of Science
2. 1. Levey AS,
   2. Stevens LA,
   3. Coresh J

   (2009) Conceptual model of CKD: applications and implications. Am J Kidney Dis 53:S4.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Abboud H,
   2. Henrich WL

   (2010) Clinical practice. Stage IV chronic kidney disease. N Engl J Med 362:56.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   1. Eremina V,
   2. Baelde HJ,
   3. Quaggin SE

   (2007) Role of the VEGF--a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 106:32–37.

   OpenUrlCrossRefPubMed
5. 1. Ferrara N

   (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280:C1358–C1366.

   OpenUrlPubMedWeb of Science
6. ↵
   1. Ferrara N,
   2. Davis-Smyth T

   (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4–25.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Wada T,
   2. Jesmin S,
   3. Gando S,
   4. Yanagida Y,
   5. Mizugaki A,
   6. Sultana SN,
   7. et al.

   (2012) Angiogenic factors and their soluble receptors predict organ dysfunction and mortality in post-cardiac arrest syndrome. Crit Care 16:R171.

   OpenUrlCrossRefPubMed
8. ↵
   1. Kendall RL,
   2. Wang G,
   3. Thomas KA

   (1996) Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226:324–328.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Kaza E,
   2. Ablasser K,
   3. Poutias D,
   4. Griffiths ER,
   5. Saad FA,
   6. Hofstaetter JG,
   7. et al.

   (2011) Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium. Cardiovasc Res 89:410–418.

   OpenUrlCrossRefPubMed
10. ↵
    1. Hornig C,
    2. Barleon B,
    3. Ahmad S,
    4. Vuorela P,
    5. Ahmed A,
    6. Weich HA

    (2000) Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 80:443–454.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Di Marco GS,
    2. Reuter S,
    3. Hillebrand U,
    4. Amler S,
    5. König M,
    6. Larger E,
    7. et al.

    (2009) The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol 20:2235–2245.

    OpenUrlAbstract/FREE Full Text
12. ↵
    1. Harper SJ,
    2. Downs L,
    3. Tomson CR,
    4. Dwight JS,
    5. Bolton C

    (2002) Elevated plasma vascular endothelial growth factor levels in non-diabetic predialysis uraemia. Nephron 90:341–343.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Pawlak K,
    2. Pawlak D,
    3. Myśliwiec M

    (2006) Possible association between circulating vascular endothelial growth factor and oxidative stress markers in hemodialysis patients. Med Sci Monit 12:CR181–CR185.

    OpenUrlPubMedWeb of Science
14. ↵
    1. Doi K,
    2. Leelahavanichkul A,
    3. Hu X,
    4. Sidransky KL,
    5. Zhou H,
    6. Qin Y,
    7. et al.

    (2008) Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome. Kidney Int 74:1017–1025.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Lenz T,
    2. Gauer S,
    3. Weich HA,
    4. Haak T,
    5. Bergner R,
    6. Gossmann J

    (2005) Vascular endothelial growth factor and its soluble receptor, Flt-1, are not correlated to erythropoietin in diabetics with normal or reduced renal function. Nephrology (Carlton) 10:84–89.

    OpenUrlPubMed
16. ↵
    1. Wada T,
    2. Jesmin S,
    3. Gando S,
    4. Sultana SN,
    5. Zaedi S,
    6. Yokota H

    (2012) Using angiogenic factors and their soluble receptors to predict organ dysfunction in patients with disseminated intravascular coagulation associated with severe trauma. Crit Care 16:R63.

    OpenUrlPubMed
17. ↵
    1. Yang KY,
    2. Liu KT,
    3. Chen YC,
    4. Chen CS,
    5. Lee YC,
    6. Perng RP,
    7. et al.

    (2011) Plasma soluble vascular endothelial growth factor receptor-1 levels predict outcomes of pneumonia-related septic shock patients: a prospective observational study. Crit Care 15:R11.

    OpenUrlPubMed
18. ↵
    1. Abboud H,
    2. Henrich WL

    (2010) Clinical practice. Stage IV chronic kidney disease. N Engl J Med 362:56–65.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    1. Clauss M,
    2. Weich H,
    3. Breier G,
    4. Knies U,
    5. Röckl W,
    6. Waltenberger J,
    7. et al.

    (1996) The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 271:17629–17634.

    OpenUrlAbstract/FREE Full Text
20. ↵
    1. Sarnak MJ,
    2. Levey AS,
    3. Schoolwerth AC,
    4. Coresh J,
    5. Culleton B,
    6. Hamm LL,
    7. et al.

    (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular. Disease High Blood Pressure Research Clinical Cardiology and Epidemiology and Prevention. Circulation 108:2154–2169.

    OpenUrlFREE Full Text
21. ↵
    1. Guo Q,
    2. Carrero JJ,
    3. Yu X,
    4. Bárány P,
    5. Qureshi AR,
    6. Eriksson M,
    7. et al.

    (2009) Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients. Nephrol Dial Transplant 24:3468–3473.

    OpenUrlCrossRefPubMedWeb of Science
22. ↵
    1. Lenz T,
    2. Gauer S,
    3. Weich HA,
    4. Haak T,
    5. Bergner R,
    6. Gossmann J

    (2005) Vascular endothelial growth factor and its soluble receptor, Flt-1, are not correlated to erythropoietin in diabetics with normal or reduced renal function. Nephrology (Carlton) 10:84–89.

    OpenUrlPubMed
23. ↵
    1. Tartare S,
    2. Mothe I,
    3. Kowalski-Chauvel A,
    4. Breittmayer JP,
    5. Ballotti R,
    6. Van Obberghen E

    (1994) Signal transduction by a chimeric insulin-like growth factor-1 (IGF-1) receptor having the carboxyl-terminal domain of the insulin receptor. J Biol Chem 269:11449–11455.

    OpenUrlAbstract/FREE Full Text
24. ↵
    1. Miele C,
    2. Rochford JJ,
    3. Filippa N,
    4. Giorgetti-Peraldi S,
    5. Van Obberghen E

    (2000) Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol Chem 275:21695–21702.

    OpenUrlAbstract/FREE Full Text
25. ↵
    1. Allanore Y,
    2. Borderie D,
    3. Lemaréchal H,
    4. Ekindjian OG,
    5. Kahan A

    (2004) Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1. Arthritis Res Ther 6:R309–R314.

    OpenUrlCrossRefPubMedWeb of Science